- Home
- TBPH vs WIW Comparison
TBPH vs WIW Comparison
Compare TBPH & WIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- WIW
- Stock Information
- Founded
- TBPH 2013
- WIW 2004
- Country
- TBPH United States
- WIW United States
- Employees
- TBPH N/A
- WIW N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- WIW Finance Companies
- Sector
- TBPH Health Care
- WIW Finance
- Exchange
- TBPH Nasdaq
- WIW Nasdaq
- Market Cap
- TBPH 464.5M
- WIW 521.9M
- IPO Year
- TBPH N/A
- WIW N/A
- Fundamental
- Price
- TBPH $10.92
- WIW $8.78
- Analyst Decision
- TBPH Strong Buy
- WIW
- Analyst Count
- TBPH 5
- WIW 0
- Target Price
- TBPH $16.60
- WIW N/A
- AVG Volume (30 Days)
- TBPH 366.7K
- WIW 229.9K
- Earning Date
- TBPH 08-04-2025
- WIW 01-01-0001
- Dividend Yield
- TBPH N/A
- WIW 11.14%
- EPS Growth
- TBPH N/A
- WIW N/A
- EPS
- TBPH N/A
- WIW N/A
- Revenue
- TBPH $65,266,000.00
- WIW N/A
- Revenue This Year
- TBPH $43.18
- WIW N/A
- Revenue Next Year
- TBPH N/A
- WIW N/A
- P/E Ratio
- TBPH N/A
- WIW N/A
- Revenue Growth
- TBPH 6.11
- WIW N/A
- 52 Week Low
- TBPH $7.44
- WIW $8.01
- 52 Week High
- TBPH $11.82
- WIW $9.37
- Technical
- Relative Strength Index (RSI)
- TBPH 60.52
- WIW 68.92
- Support Level
- TBPH $10.46
- WIW $8.54
- Resistance Level
- TBPH $11.44
- WIW $8.80
- Average True Range (ATR)
- TBPH 0.27
- WIW 0.06
- MACD
- TBPH -0.01
- WIW 0.02
- Stochastic Oscillator
- TBPH 56.65
- WIW 94.33
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.